Resources from the same session
Current indications of precision therapeutics in advanced oncogene-addicted NSCLC beyond EGFR and ALK: Efficacy, safety, value
Presenter: Benjamin Besse
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
The quest for optimal integration of biomarker testing by tissue NGS in the care pathway: Analytics, availability and reporting of actionable vs non-actionable aberrations
Presenter: Javier Hernandez-Losa
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Q&A
Presenter: Solange Peters
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Highlighting the value of Molecular Tumour Boards: Presentation of two patient cases with oncogene-addicted NSCLC, summary of clinical evidence and insights in molecular profiling/interpretation
Presenter: Simon Ekman
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Concluding remarks
Presenter: Benjamin Besse
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast